PTC Therapeutics: exec. vp and clo Mark Elliott Boulding sold 192 shares

What happened

• Mark Elliott Boulding, exec. vp and clo, exercised options to acquire 192 shares at $39.42 on Oct 9, 2026, costing $7,569, and sold 192 shares in open-market sales at a weighted average price of $64.26 on Oct 9, 2026, for $12,338. The filing also reports a derivative disposition of 192 shares at $0.00.

Key details

• Transaction dates and prices: Oct 9, 2026 — exercised 192 shares @ $39.42 (code M) and sold 192 shares @ $64.26 (code S); the sale price is a weighted average of trades at prices ranging from $64.00 to $64.70 per share (footnote F2). The filing also lists a derivative disposition of 192 shares @ $0.00 (code M).
• Shares owned after the transaction: not reported in this filing.
• Relevant footnotes: F1 — transaction effected pursuant to a written Rule 10b5-1 plan adopted Sep 10, 2025; F2 — sale price is a weighted average of multiple trades at $64.00 to $64.70; F3 — option was granted Jan 5, 2023, with a four-year vesting schedule (25% on Jan 5, 2024, then 6.25% of the original grant each quarter beginning Apr 5, 2024).
• Filing date: Oct 13, 2026; filing timeliness is not indicated in the reported information.

Why it may matter

• The filing shows an option exercise followed by the sale of the resulting shares on the same day, consistent with a cashless exercise where shares are sold at once. This filing does not show why the insider traded or why the company acted.